Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Nabs Pole Position in RNAi With $1.1 Billion Sirna Buy

Executive Summary

Merck's takeout of Sirna gives a boost to platform biotech investors and has allowed Merck to stake an expansive claim in RNAi. The deal caps a massive turnaround for Sirna--previously Ribozyme Pharmaceuticals--and rewards the investors who took an early chance on RNAi therapies. The move should pay off handsomely for Merck, now the leader in RNAi, provided the technology turns out to be the next Antibodies, not the next Antisense.
Advertisement
Advertisement

Related Content

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002680

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel